ecancer
ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.
ASCO® 2023
ecancer
2023 ASCO® Insights: "TRANSCEND CLL-004 Study of Liso-cel in R/R CLL/SLL"
FEATURING
Tanya Siddiqi
- 44 views
- July 5, 2023
ecancer
ASCO® 2023 Insights: "NAPOLI 3 Analysis of 1L NALIRIFOX vs. Gem + nab-Paclitaxel for mPDAC"
FEATURING
Eileen O’Reilly
- 273 views
- July 5, 2023
- 1
ecancer
ASCO® 2023 Summary: "Analysis of Key Studies in Lung Cancer - ADAURA, KEYNOTE-671, KEYNOTE-789 & LUNAR"
FEATURING
Luis Raez
- 423 views
- July 5, 2023
- 3
ecancer
ASCO® 2023 Summary: "PanTumor Conference Highlights Including INDIGO, IMbrave050 & TALAPRO-2 Trials"
FEATURING
Bishal Gyawali
- 211 views
- June 27, 2023
- 1
ecancer
ASCO® 2023 Insights: "CONTINUUM Trial Data on Sintilimab + Chemo in High-Risk Locoregionally-Advanced Nasopharyngeal Carcinoma"
FEATURING
Jun Ma
- 41 views
- June 15, 2023
ecancer
ASCO® 2023 Insights: "Concurrent CRT Followed by Adjuvant Cisplatin-Gemcitabine in N2-3 Nasopharyngeal Carcinoma"
FEATURING
Lin-Quan Tang
- 22 views
- June 15, 2023
ecancer
ASCO® 2023 Summary: "Current Treatment Landscape for Advanced Bladder Cancer"
FEATURING
Arlene Siefker-Radtke,
Yohann Loriot
- 199 views
- June 15, 2023
ecancer
ASCO® 2023 Insights: "IMbrave050 Data on Atezolizumab + Bevacizumab vs. Active Surveillance in HCC"
FEATURING
Masatoshi Kudo
- 136 views
- June 15, 2023
- 1
ecancer
ASCO® 2023 Insights: "New Data From KEYNOTE-942 on DMFS With Adjuvant mRNA-4157 + Pembro in High-Risk Melanoma"
FEATURING
Muhammad Adnan Khattak
- 42 views
- June 15, 2023
ecancer
ASCO® 2023 Insights: "PRODIGE 23 Trial on Neoadjuvant Chemo + mFOLFIRINOX in Locally Advanced RC"
FEATURING
Thierry Conroy
- 179 views
- June 15, 2023
ecancer
ASCO® 2023 Insights: "KEYNOTE-716 Results on Pembro Use in Stage IIB/IIC Melanoma"
FEATURING
Jason Luke
- 182 views
- June 15, 2023
ecancer
ASCO® 2023 Insights: "2L Triple Metronomic Chemo vs. Systemic Therapy for HNC"
FEATURING
Rushabh Kiran Kothari
- 45 views
- June 15, 2023
ecancer
ASCO® 2023 Insights: "PHERGain Data on Dual HER2 Blockade Without Chemo in Early Stage BC"
FEATURING
Javier Cortes
- 218 views
- June 15, 2023
- 3
ecancer
ASCO® 2023 Insights: "Short-HER Data on Nine-Weeks vs. One-Year Trastuzumab in Early Stage HER2+ BC"
FEATURING
Pierfranco Conte
- 181 views
- June 15, 2023
- 1
ecancer
ASCO® 2023 Insights: "SONIA Trial Summary on 1L Use of CDK4/6i + ET vs. 2L Use in HR+/HER2- Advanced BC"
FEATURING
Gabe Sonke
- 349 views
- June 15, 2023
- 3
ecancer
ASCO® 2023 Insights: "A Systematic Review and Meta-Analysis of Prognostic Value of HER2-Low Status in BC"
FEATURING
Chiara Molinelli
- 31 views
- June 15, 2023
ecancer
ASCO® 2023 Insights: "Novel FolRα-Targeting ADC Luveltamab Tazevibulin in Recurrent Epithelial Ovarian Cancer"
FEATURING
Ana Oaknin
- 80 views
- June 15, 2023
ecancer
ASCO® 2023 Insights: "DESTINY-PanTumor02 Data on T-DXd Response in Multiple Tumor Types"
FEATURING
Funda Meric-Bernstram
- 80 views
- June 15, 2023
ecancer
ASCO® 2023 Insights: "RUBY Trial Summary on Dostarlimab + Chemo for Primary Advanced or Recurrent Endometrial Cancer"
FEATURING
Matthew Powell
- 215 views
- June 15, 2023
- 1
ecancer
ASCO® 2023 Insights: "Phase III NATALEE Trial - Ribociclib + ET as Adjuvant Treatment in Patients With HR+/HER2- eBC"
FEATURING
Dennis Slamon
- 950 views
- June 14, 2023
- 2
ecancer
ASCO® 2023 Summary: "Key Studies in Early Breast Cancer"
FEATURING
Matteo Lambertini
- 688 views
- June 14, 2023
- 3
ecancer
ASCO® 2023 Insights: "Pembro in 1L Treatment for Unresectable Advanced Pleural Mesothelioma"
FEATURING
Penelope Bradbury
- 35 views
- June 14, 2023
ecancer
ASCO® 2023 Insights: "Next-Generation Selective RET Inhibitor in RET-Altered Solid Tumors"
FEATURING
Qing Zhou
- 18 views
- June 14, 2023
ecancer
ASCO® 2023 Insights: "TRIMM-2 Study Summary - Update on Talquetamab + Daratumumab for R/R MM"
FEATURING
Bhagirathbhai Dholaria
- 67 views
- June 14, 2023
ecancer
ASCO® 2023 Insights: "S1826 Study Summary - Nivolumab-AVD vs. Brentuximab Vedotin-AVD in Pts With Advanced Stage HL"
FEATURING
Alex Herrera
- 73 views
- June 14, 2023
ecancer
ASCO® 2023 Insights: "CARTITUDE-4 Study Summary - Cilta-Cel Vs. SOC in Len-Refractory MM"
FEATURING
Binod Dhakal
- 291 views
- June 14, 2023
- 2
ecancer
ASCO® 2023 Insights: "Elranatamab in Patients With R/R MM Previously Exposed to BCMA-Directed Therapies"
FEATURING
Ajay Nooka
- 31 views
- June 14, 2023
ecancer
ASCO® 2023 Insights: "ZUMA-7 Study Summary - Axi-Cel in Early R/R Large B-Cell Lymphoma"
FEATURING
Jason Westin
- 61 views
- June 14, 2023
ecancer
ASCO® 2023 Insights: "Teclistamab for R/R MM - Summary of Long-Term Follow Up Data From MajesTEC-1"
FEATURING
Niels Van De Donk
- 87 views
- June 14, 2023
ecancer
ASCO® 2023 Summary: "Latest in PARPi in Prostate Cancer - PROpel, TALAPRO-2, and MAGNITUDE Trials"
- 616 views
- June 14, 2023
- 6
ecancer
ASCO® 2023 Insights: "Phase 3 LUNAR Study - Tumor Treating Fields Therapy for mNSCLC After Platinum Failure"
FEATURING
Ticiana Leal
- 242 views
- June 14, 2023
- 1
ecancer
FDA Updates: TALAPRO-2 Phase 3 Study - Talazoparib + Enzalutamide in 1L HRR mCRPC
FEATURING
Karim Fizazi
- 216 views
- June 14, 2023
- 1
